These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 18205834)

  • 21. From protein to peptides: a spectrum of non-hydrolytic functions of acetylcholinesterase.
    Halliday AC; Greenfield SA
    Protein Pept Lett; 2012 Feb; 19(2):165-72. PubMed ID: 21933122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathological and biochemical alterations of astrocytes in ovariectomized rats injected with D-galactose: a potential contribution to Alzheimer's disease processes.
    Hua X; Lei M; Ding J; Han Q; Hu G; Xiao M
    Exp Neurol; 2008 Apr; 210(2):709-18. PubMed ID: 18289535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to improve neuroprotection in Parkinson's disease?
    Hirsch EC
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S332-5. PubMed ID: 18267260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease.
    Gongadze N; Antelava N; Kezeli T; Okudjava M; Pachkoria K
    Georgian Med News; 2008 Feb; (155):44-8. PubMed ID: 18401056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease.
    Kazantsev AG; Kolchinsky AM
    Arch Neurol; 2008 Dec; 65(12):1577-81. PubMed ID: 19064744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.
    Rosini M; Simoni E; Bartolini M; Cavalli A; Ceccarini L; Pascu N; McClymont DW; Tarozzi A; Bolognesi ML; Minarini A; Tumiatti V; Andrisano V; Mellor IR; Melchiorre C
    J Med Chem; 2008 Aug; 51(15):4381-4. PubMed ID: 18605718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Author response.
    Bohnen N; Sarter M; Muller M; Dauer W; Albin R
    Neurology; 2014 Apr; 82(17):1568-9. PubMed ID: 24895748
    [No Abstract]   [Full Text] [Related]  

  • 28. Lesions and genes: on the edge of improved isomorphic models for Alzheimer's disease?
    Gonzalez de Aguilar JL; Loeffler JP; Boutillier AL
    Neurodegener Dis; 2008; 5(5):318-20. PubMed ID: 18520166
    [No Abstract]   [Full Text] [Related]  

  • 29. Plant signalling peptides: some recent developments.
    Bahyrycz A; Konopińska D
    J Pept Sci; 2007 Dec; 13(12):787-97. PubMed ID: 17890638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Author response.
    Bohnen NI; Kotagal V; Albin R; Muller M
    Neurology; 2014 Jul; 83(1):103. PubMed ID: 25110786
    [No Abstract]   [Full Text] [Related]  

  • 31. Acetylcholinesterase activity of different brain areas in Parkinson's disease.
    Rinne UK; Riekkinen PJ; Laaksonen H; Sonninen VJ
    Acta Neurol Scand Suppl; 1972; 51():137-8. PubMed ID: 4514342
    [No Abstract]   [Full Text] [Related]  

  • 32. Rivastigmine in Parkinson's disease dementia.
    Chitnis S; Rao J
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Signaling of the neurotrophin receptor p75 in relation to Alzheimer's disease.
    Diarra A; Geetha T; Potter P; Babu JR
    Biochem Biophys Res Commun; 2009 Dec; 390(3):352-6. PubMed ID: 19818333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of multiple protein kinases in cPLA2 phosphorylation, arachidonic acid release, and cell death in in vivo and in vitro models of 1-methyl-4-phenylpyridinium-induced parkinsonism--the possible key role of PKG.
    Chalimoniuk M; Stolecka A; Ziemińska E; Stepień A; Langfort J; Strosznajder JB
    J Neurochem; 2009 Jul; 110(1):307-17. PubMed ID: 19457107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the p75 neurotrophin receptor in cholinergic dysfunction in Alzheimer's disease.
    Coulson EJ; May LM; Sykes AM; Hamlin AS
    Neuroscientist; 2009 Aug; 15(4):317-23. PubMed ID: 19458382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation--relevance in a mouse model of Parkinson's disease.
    Thomas T; Timmer M; Cesnulevicius K; Hitti E; Kotlyarov A; Gaestel M
    J Neurochem; 2008 Jun; 105(5):2039-52. PubMed ID: 18298661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why do Alzheimer's disease and Parkinson's disease target the same neurons?
    Eggers AE
    Med Hypotheses; 2009 Jun; 72(6):698-700. PubMed ID: 19250756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The essential role of lipids in Alzheimer's disease.
    Florent-Béchard S; Desbène C; Garcia P; Allouche A; Youssef I; Escanyé MC; Koziel V; Hanse M; Malaplate-Armand C; Stenger C; Kriem B; Yen-Potin FT; Olivier JL; Pillot T; Oster T
    Biochimie; 2009 Jun; 91(6):804-9. PubMed ID: 19303044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
    Pei JJ; Sjögren M; Winblad B
    Curr Opin Psychiatry; 2008 Nov; 21(6):555-61. PubMed ID: 18852562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respective roles of the catalytic domains and C-terminal tail peptides in the oligomerization and secretory trafficking of human acetylcholinesterase and butyrylcholinesterase.
    Liang D; Blouet JP; Borrega F; Bon S; Massoulié J
    FEBS J; 2009 Jan; 276(1):94-108. PubMed ID: 19019080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.